Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health
L- + , L-
In addition to having effects on how your body metabolizes glucose and processes certain hormones, GLP-1 receptor agonists, as well as dual agonists like tirzepatide, act on receptors in your brain to curb cravings
Heres who might be able to use them: Adults With Higher BMI You might qualify for GLP-1 weight loss medication if: Your BMI is 30 or higher, or Your BMI is 27 or higher and you have weight-related health problems BMI (Body Mass Index) is a way to measure if your weight might affect your health
Early animal studies and small human trials suggested DSIP might influence sleep latency and sleep efficiency, although the reported effects were generally weak and not consistently different from placebo
